<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="53665">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02407548</url>
  </required_header>
  <id_info>
    <org_study_id>SunYat-senU002</org_study_id>
    <nct_id>NCT02407548</nct_id>
  </id_info>
  <brief_title>The Effects of Dietary Supplement of Coenzyme Q10（CoQ10） on Dyslipidemia</brief_title>
  <acronym>TEDSCD</acronym>
  <official_title>The Effects of Dietary Supplement of Coenzyme Q10 on Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In previous study the investigators found that CoQ10 can improve cholesterol efflux from
      macrophages in cell model, ApoE mice model and small-scale of healthy volunteers. In
      addition, CoQ10 has strong antioxidant activity and is an essential factor of mitochondria
      electron transport chain. So the investigators hypothesize that CoQ10 may have some health
      promotion effect on dyslipidemia, risk factor of atherosclerosis and other cardiovascular
      diseases. On this purpose, the investigators are going to recruit 150 dyslipidemia patients
      to supply CoQ10+vitamin E or CoQ10 alone or placebo in different doses for 24 weeks to
      explore the effects of CoQ10 on cholesterol efflux and lipid profiles on dyslipidemia.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of CoQ10 on high-density lipoprotein cholesterol</measure>
    <time_frame>6 months</time_frame>
    <description>HDL-c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of CoQ10 on cholesterol efflux from macrophages</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of CoQ10 on total cholesterol</measure>
    <time_frame>6 months</time_frame>
    <description>TC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of CoQ10 on triglycerides</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of CoQ10 on low density lipoprotein cholesterin</measure>
    <time_frame>6 months</time_frame>
    <description>LDL-c</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of CoQ10 on apolipoprotein A1</measure>
    <time_frame>6 months</time_frame>
    <description>ApoA-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of CoQ10 on apolipoprotein B</measure>
    <time_frame>6 months</time_frame>
    <description>ApoB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of CoQ10 on blood glucose and insulin</measure>
    <time_frame>6 mouth</time_frame>
    <description>reflect insulin sensibility</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Effects of CoQ10 on FGF21</measure>
    <time_frame>6 month</time_frame>
    <description>reflect glucose and lipid metabolism</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>high dose combined group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>each coenzyme Q10 vitamin E softgel contain CoQ 10 30mg + vitamin E 16mg; The subjects in this arm take 2 softgels after lunch and supper respectively per day. Total supplementation is 120mgCoQ10 and 64mg vitamin per day. The duration is 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose CoQ10 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>each softgel contain CoQ 10 30mg; The subjects in this arm take 2 softgels after lunch and supper respectively per day. Total supplementation is 120mgCoQ10 per day. The duration is 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose placebo group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>each softgel contain no vitamin E, no CoQ10; The subjects in this arm take 2 softgels after lunch and supper respectively per day. The duration is 24 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose CoQ10 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>each softgel contain CoQ 10 30mg; The subjects in this arm take 1 softgel after lunch and supper respectively per day. Total supplementation is 60mgCoQ10 per day. The duration is 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low dose placebo group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>each softgel contain no vitamin E, no CoQ10; The subjects in this arm take 1 softgel after lunch and supper respectively per day. The duration is 24 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>coenzyme Q10 vitamin E softgel</intervention_name>
    <description>4 coenzyme Q10 and vitamin E softgels per day for 24 weeks. Keep normal lift style unchanged.</description>
    <arm_group_label>high dose combined group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>coenzyme Q10 softgel</intervention_name>
    <description>4 coenzyme Q10 softgels per day for 24 weeks. Keep normal lift style unchanged.</description>
    <arm_group_label>high dose CoQ10 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo softgel</intervention_name>
    <description>4 placebo softgels per day. Keep normal lift style unchanged.</description>
    <arm_group_label>high dose placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>coenzyme Q10 softgel</intervention_name>
    <description>2 coenzyme Q10 softgels per day for 24 weeks. Keep normal lift style unchanged.</description>
    <arm_group_label>Low dose CoQ10 group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo softgel</intervention_name>
    <description>2 placebo softgels per day for 24 weeks. Keep normal lift style unchanged.</description>
    <arm_group_label>Low dose placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subjects were considered to have dyslipidemia if they met 2 of the following 4
             criteria:

               -  fasting total cholesterol concentration&gt;200 mg/dL,

               -  fasting triglyceride concentration&gt;150mg/dL,

               -  fasting LDL-cholesterol concentrations&gt;100 mg/dL, or

               -  fasting HDL-cholesterol concentrations&gt;40 mg/dL.

        Exclusion Criteria:

          -  history of CVD or other severe chronic disease or use of any drugs known to affect
             lipid metabolism.

          -  use any antioxidant such as Vitamin E, vitamin C,Phytochemicals and coenzyme Q10
             within two months before trial.

          -  pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>ling wenhua, professor</last_name>
    <role>Study Director</role>
    <affiliation>SUN YAY-SEN UNIVERSITY</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>zhang peiwen, PHD</last_name>
    <phone>15820231739</phone>
    <email>313743920@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hongshan Street community health service centre</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhang lian fang, undergraduate</last_name>
      <phone>020-62953185</phone>
      <email>278029429@qq.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 24, 2017</lastchanged_date>
  <firstreceived_date>March 25, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>zhangpeiwen</investigator_full_name>
    <investigator_title>PhD candidate</investigator_title>
  </responsible_party>
  <keyword>cholesterol efflux</keyword>
  <keyword>dyslipidemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
